obesity-995x60.png
FEATURED ARTICLES
Helus Shares Experience Studying Adjunctive Psychedelic For Major Depressive Disorder
Helus Pharma CMO Amir Inamdar discusses the strategic rationale behind its Phase 3 trial for major depressive disorder, including its adjunctive-treatment approach, patient population selection, and endpoint strategy.
-
RWE Increasingly Supports Rare Disease Research As RCTs Alone Fall Short
Chiesi's Rachele Berria, MD, Ph.D., discusses how RWE is reshaping rare disease drug development strategies, from leveraging registries and patient-reported outcomes to navigating evolving regulatory expectations.
-
AI Can Help Design Better Trials, But It Still Can't Tell You Whether Patients Will Join Them
AI is changing the way clinical trial trials are discussed, planned, and designed. But even with an improved protocol, are AI-enhanced trials driving better enrollment?
-
The Triple Effect Of Community-Based Clinical Trials
Taking trials into local communities improves access, boosts enrollment, reduces dropouts, and yields more representative data, speeding timelines and strengthening study quality.